PURPOSE: To describe the baseline characteristics of a large international cohort of patients with macular telangiectasia type 2 (MacTel Type 2) in anticipation of a longitudinal natural history study to evaluate structural and functional changes, identify potential risk factors and related outcomes. METHODS: Images including fundus photographs, fluorescein angiograms, optical coherence tomography and fundus autofluorescence were collected. A grading system for MacTel type 2 was developed by the central reading center to evaluate lesion characteristics. Relationships between lesion characteristics and visual acuity were evaluated. RESULTS: A total of 310 participants have been enrolled in the study. The mean time since diagnosis was 3 years (range 0 to 25 years). The mean age at the baseline examination was 61 +/- 9 years. The mean visual acuity in the better eye was approximately 20/32 Snellen equivalents and approximately 20/50 in the worse eye. The visual acuity in the better eye of half of the participants was 20/32 or better. We found some relationships between visual acuity and lesions characteristic of MacTel Type 2. CONCLUSIONS: This is the first large-scale study of patients with MacTel Type 2. More than half of the patients had 20/32 or better vision in their better eye, which is a sign that decreased function in these participants may not be reflected in central visual acuity. These findings highlight the limitation of using visual acuity measurements as a measure of function and as an outcome measure in potential clinical trials in patients with MacTel Type 2.
PURPOSE: To describe the baseline characteristics of a large international cohort of patients with macular telangiectasia type 2 (MacTel Type 2) in anticipation of a longitudinal natural history study to evaluate structural and functional changes, identify potential risk factors and related outcomes. METHODS: Images including fundus photographs, fluorescein angiograms, optical coherence tomography and fundus autofluorescence were collected. A grading system for MacTel type 2 was developed by the central reading center to evaluate lesion characteristics. Relationships between lesion characteristics and visual acuity were evaluated. RESULTS: A total of 310 participants have been enrolled in the study. The mean time since diagnosis was 3 years (range 0 to 25 years). The mean age at the baseline examination was 61 +/- 9 years. The mean visual acuity in the better eye was approximately 20/32 Snellen equivalents and approximately 20/50 in the worse eye. The visual acuity in the better eye of half of the participants was 20/32 or better. We found some relationships between visual acuity and lesions characteristic of MacTel Type 2. CONCLUSIONS: This is the first large-scale study of patients with MacTel Type 2. More than half of the patients had 20/32 or better vision in their better eye, which is a sign that decreased function in these participants may not be reflected in central visual acuity. These findings highlight the limitation of using visual acuity measurements as a measure of function and as an outcome measure in potential clinical trials in patients with MacTel Type 2.
Authors: Traci E Clemons; Mark C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria Figueroa; Molly W Harrington Journal: Invest Ophthalmol Vis Sci Date: 2008-06-27 Impact factor: 4.799
Authors: Hans-Martin Helb; Peter Charbel Issa; Rob L P VAN DER Veen; Tos T J M Berendschot; Hendrik P N Scholl; Frank G Holz Journal: Retina Date: 2008-06 Impact factor: 4.256
Authors: Irene A Barbazetto; Miia Room; Nicholas A Yannuzzi; Gaetano R Barile; Joanna E Merriam; Anne M C Bardal; K Bailey Freund; Lawrence A Yannuzzi; Rando Allikmets Journal: Invest Ophthalmol Vis Sci Date: 2008-05-23 Impact factor: 4.799
Authors: Ferenc B Sallo; Irene Leung; Mina Chung; Ute E K Wolf-Schnurrbusch; Alfredo Dubra; David R Williams; Traci Clemons; Daniel Pauleikhoff; Alan C Bird; Tunde Peto Journal: Ophthalmology Date: 2011-08-12 Impact factor: 12.079
Authors: Daniel Pauleikhoff; Roberto Bonelli; Adam M Dubis; Frederic Gunnemann; Kai Rothaus; Peter Charbel Issa; Tjebo Fc Heeren; Tunde Peto; Traci E Clemons; Emily Y Chew; Alan C Bird; Ferenc B Sallo Journal: Acta Ophthalmol Date: 2019-04-09 Impact factor: 3.761
Authors: Thomas S Scerri; Anna Quaglieri; Carolyn Cai; Jana Zernant; Nori Matsunami; Lisa Baird; Lea Scheppke; Roberto Bonelli; Lawrence A Yannuzzi; Martin Friedlander; Catherine A Egan; Marcus Fruttiger; Mark Leppert; Rando Allikmets; Melanie Bahlo Journal: Nat Genet Date: 2017-02-27 Impact factor: 38.330
Authors: Qinyun Wang; William S Tuten; Brandon J Lujan; Jennifer Holland; Paul S Bernstein; Steven D Schwartz; Jacque L Duncan; Austin Roorda Journal: Invest Ophthalmol Vis Sci Date: 2015-01-13 Impact factor: 4.799
Authors: Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird Journal: Invest Ophthalmol Vis Sci Date: 2012-11-29 Impact factor: 4.799
Authors: Annal D Meleth; Brian C Toy; Divya Nigam; Elvira Agrón; Robert P Murphy; Emily Y Chew; Wai T Wong Journal: Retina Date: 2013-04 Impact factor: 4.256
Authors: Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl Journal: Prog Retin Eye Res Date: 2012-12-03 Impact factor: 21.198